Jose M Mejia Oneto
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2021First federal award
$9.5MFederal grants as PI10 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
10 awards · $9.5M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 18, 2026 | NIH | SBIR Phase II CEACAM5-targeted activation of potent chemotherapeutics via bioorthogonal click chemistry | $1.1M | SHASQI, INC. |
| Sep 24, 2025 | NIH | SBIR Phase II CEACAM5-targeted activation of potent chemotherapeutics via bioorthogonal click chemistry | $1.1M | SHASQI, INC. |
| Sep 12, 2025 | NIH | SBIR Phase II Antigen-targeted activation of Topo1 inhibitors via click chemistry | $432K | SHASQI, INC. |
| Sep 6, 2024 | NIH | SBIR Phase II Antigen-targeted activation of Topo1 inhibitors via click chemistry | $1.6M | SHASQI, INC. |
| Aug 13, 2024 | NIH | SBIR Phase II Antibody-guided localized activation of bioorthogonal protodrugs via click chemistry | $1.2M | SHASQI, INC. |
| Mar 18, 2024 | NIH | SBIR Phase II Assessing the safety and efficacy of SQ3370 in a phase 1b dose-expansion cohort at the recommended Phase 2 dose in patients with advanced sarcoma | $322K | SHASQI, INC. |
| Mar 24, 2023 | NIH | SBIR Phase II Assessing the safety and efficacy of SQ3370 in a phase 1b dose-expansion cohort at the recommended Phase 2 dose in patients with advanced sarcoma | $299K | SHASQI, INC. |
| Apr 1, 2022 | NIH | SBIR Phase II Immune Biomarker Assessment and Manufacturing Development for SQ3370-001, a first-in-human phase I dose-escalation clinical trial to test a novel treatment against advanced solid tumors | $801K | SHASQI, INC. |
| Sep 16, 2021 | NIH | SBIR Phase II Assessing the safety and efficacy of SQ3370 in a phase 1b dose-expansion cohort at the recommended Phase 2 dose in patients with advanced sarcoma | $1.4M | SHASQI, INC. |
| Apr 1, 2021 | NIH | SBIR Phase II Immune Biomarker Assessment and Manufacturing Development for SQ3370-001, a first-in-human phase I dose-escalation clinical trial to test a novel treatment against advanced solid tumors | $1.2M | SHASQI, INC. |
Peer ranks
Federal funding#71
Awards as PI#128
Patents#273
Companies
- SHASQI, INC.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.